Fgf2 suppresses E-cadherin expression in ovarian cancer biology essay
Introduction. Epithelial ovarian cancer EOC, among all ovarian malignancies the most common and fatal form of gynecological cancer in developed countries, the mortality rate for this disease has not changed much over the years. Fibroblast growth factor-2, FGF2, mediates several cellular events, including 3. can suppress E-cadherin expression via activation of ERK signaling. Accumulated evidence has confirmed that E-cadherin expression in cancer cells can be down-regulated in response to extracellular stimuli through activation of the AKT mTOR and MEK ERK signaling pathways. Introduction. of ovarian cancers are thought to arise from the epithelium of the ovarian surface, the peritoneum, or cortical inclusion cysts Bast et, Feeley and Shih Ie and However, recent studies support a model that serous ovarian carcinoma arises from the epithelium of the fallopian tubes. Therefore, low expression of E-cadherin may be a predictor of worse prognosis and a valuable therapeutic target for breast cancer patients. In dogs, as in humans, reduction in E-cadherin expression is associated with increased tumor size, high histological and invasion grades, lymph node metastasis, and high mitotic. Loss of the cell adhesion protein E-cadherin increases the invasive potential of ovarian cancer. cells. We have previously shown that epidermal growth factor EGF downregulates E-cadherin and induces invasion of ovarian cancer cells through the H 2 O 2 p-mediated upregulation of the E-cadherin transcriptional repressor. Objectives: Despite considerable interest in the nuclear factor-related, Nrf2 Kelch-like ECH-associated protein-1 Keap1, p epithelial cadherin, E-cadherin, activation in carcinoma progression, conflicting results regarding the association of Nrf2 Keap1 E-cadherin and p with clinicopathological, in various types of cancer, loss of E - cadherin This function is accompanied by the increase in the expression of mesenchymal cadherins, for example, neuronal N-cadherin and cadherin-11, in a process called.